Literature DB >> 18006062

TLR4 signaling induces functional nerve growth factor receptor p75NTR on mouse dendritic cells via p38MAPK and NF-kappa B pathways.

Yingming Jiang1, Guoyou Chen, Yuanyuan Zheng, Lin Lu, Cong Wu, Yi Zhang, Qiuyan Liu, Xuetao Cao.   

Abstract

Many neuropeptides that are produced by immune cells have been shown to be involved in the pathogenesis of immunological disorders. Nerve growth factor (NGF) and its receptors are found to be widely expressed in the immune system and regulate both innate and adaptive immune responses. However, the underlying mechanisms by which NGF contributes to pathogenesis of inflammatory diseases remain to be fully understood. Dendritic cells (DCs) are potent initiator for inflammatory and immune responses upon recognization and activation of Toll-like receptors (TLRs). In this study, we demonstrated that stimulation with TLR ligand lipopolysaccharide (LPS), but not lipoteichoic acid (LTA), Poly (I:C) and CpG oligodeoxynucleotide (ODN), could significantly induce expression of NGF and NGF receptor p75(NTR) on mouse bone marrow-derived DCs (BMDCs) in vitro in dose- and time-dependent manners. The expression of NGF and NGF receptor p75(NTR) also increased on splenic DCs isolated from the mice injected with LPS in vivo. However, there was no such effect on DCs derived from TLR4-deficient mice, indicating the LPS-induced upregulation of NGF and p75(NTR) was TLR4 pathway-dependent. Furthermore, LPS-induced upregulation of NGF and p75(NTR) could be inhibited by p38MAPK inhibitor SB203580 and NF-kappaB inhibitor PDTC, suggesting TLR4-triggered activation of p38MAPK and NF-kappaB pathways are responsible for the process. Interestingly, NGF could markedly promote LPS-pretreated BMDCs to secret IL-12p40 and TNF-alpha, which could be abolished by pretreatment with p75(NTR) antagonist or the specific small interference RNA duplex targeting p75(NTR) (p75-siRNA), suggesting the inducible p75(NTR) is critical for the TLR4-initiated inflammatory effect of NGF on BMDCs. Thus, TLR4 signaling can induce expression of NGF and p75 (NTR) on DCs via activation of p38 MAPK and NF-kappaB pathways, suggesting that NGF may be involved in the pathogenesis of inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18006062     DOI: 10.1016/j.molimm.2007.10.008

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  12 in total

1.  Involvement of toll-like receptor 4 in alveolar bone loss and glucose homeostasis in experimental periodontitis.

Authors:  K Watanabe; T Iizuka; A Adeleke; L Pham; A E Shlimon; M Yasin; P Horvath; T G Unterman
Journal:  J Periodontal Res       Date:  2010-09-22       Impact factor: 4.419

Review 2.  Schwann cell interactions with axons and microvessels in diabetic neuropathy.

Authors:  Nádia P Gonçalves; Christian B Vægter; Henning Andersen; Leif Østergaard; Nigel A Calcutt; Troels S Jensen
Journal:  Nat Rev Neurol       Date:  2017-01-30       Impact factor: 42.937

3.  Mycobacterium avium subsp. paratuberculosis fibronectin attachment protein activates dendritic cells and induces a Th1 polarization.

Authors:  Jun Sik Lee; Sung Jae Shin; Michael T Collins; In Duk Jung; Young-Il Jeong; Chang-Min Lee; Yong Kyoo Shin; Daejin Kim; Yeong-Min Park
Journal:  Infect Immun       Date:  2009-04-27       Impact factor: 3.441

4.  Nerve growth factor modulates toll-like receptor (TLR) 4 and 9 expression in cultured primary VKC conjunctival epithelial cells.

Authors:  Alessandra Micera; Barbara Stampachiacchiere; Eduardo Maria Normando; Alessandro Lambiase; Sergio Bonini; Stefano Bonini
Journal:  Mol Vis       Date:  2009-10-13       Impact factor: 2.367

5.  High mechanical strain of primary intervertebral disc cells promotes secretion of inflammatory factors associated with disc degeneration and pain.

Authors:  Rahul Gawri; Derek H Rosenzweig; Emerson Krock; Jean A Ouellet; Laura S Stone; Thomas M Quinn; Lisbet Haglund
Journal:  Arthritis Res Ther       Date:  2014-01-23       Impact factor: 5.156

6.  A novel antagonist of p75NTR reduces peripheral expansion and CNS trafficking of pro-inflammatory monocytes and spares function after traumatic brain injury.

Authors:  Sangmi Lee; Aaron Mattingly; Amity Lin; Jeffrey Sacramento; Leda Mannent; Marie-Noelle Castel; Benoit Canolle; Sandrine Delbary-Gossart; Badia Ferzaz; Josh M Morganti; Susanna Rosi; Adam R Ferguson; Geoffrey T Manley; Jacqueline C Bresnahan; Michael S Beattie
Journal:  J Neuroinflammation       Date:  2016-04-22       Impact factor: 8.322

7.  Rhamnogalacturonan II is a Toll-like receptor 4 agonist that inhibits tumor growth by activating dendritic cell-mediated CD8+ T cells.

Authors:  Sung Nam Park; Kyung Tae Noh; Young-Il Jeong; In Duk Jung; Hyun Kyu Kang; Gil Sun Cha; Su Jung Lee; Jong Keun Seo; Dae Hwan Kang; Tae-Ho Hwang; Eun Kyung Lee; Byungsuk Kwon; Yeong-Min Park
Journal:  Exp Mol Med       Date:  2013-02-08       Impact factor: 8.718

8.  Soluble toll-like receptor 4 reversed attenuating effect of Chinese herbal Xiao-Qing-Long-Tang on allergen induced nerve growth factor and thymic stromal lymphopoietin.

Authors:  Ren-Shiu Chang; Yu-Chin Wang; Shung-Te Kao
Journal:  Exp Ther Med       Date:  2013-09-13       Impact factor: 2.447

9.  Lung dendritic cells undergo maturation and polarization towards a T helper type 2-stimulating phenotype in a mouse model of asthma: Role of nerve growth factor.

Authors:  Qingwu Qin; Zhan Wang; Pinhua Pan; Zu Cao; Qing Xia; Hongyi Tan; Chengping Hu
Journal:  Exp Ther Med       Date:  2014-09-15       Impact factor: 2.447

10.  Neurotrophin Receptor p75NTR Regulates Immune Function of Plasmacytoid Dendritic Cells.

Authors:  Joanna Bandoła; Cornelia Richter; Martin Ryser; Arshad Jamal; Michelle P Ashton; Malte von Bonin; Matthias Kuhn; Benjamin Dorschner; Dimitra Alexopoulou; Katrin Navratiel; Ingo Roeder; Andreas Dahl; Christian M Hedrich; Ezio Bonifacio; Sebastian Brenner; Sebastian Thieme
Journal:  Front Immunol       Date:  2017-08-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.